Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
natural killer and natural killer T cell therapy
- Development stage
- Unknown
- Lead developer
- Wenxiang Wang
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Natural killer (NK) and natural killer T (NKT) cell therapy is an investigational adoptive cellular immunotherapy developed by Wenxiang Wang for the treatment of non-small cell lung cancer (NSCLC). The treatment involves the ex vivo expansion and activation of a combination of NK cells and NKT cells, which are then administered to the patient via intravenous infusion. NK cells are innate immune cells that can directly lyse tumor cells through a variety of activating receptors (such as NKG2D) without prior sensitization. NKT cells are a specialized subset of T cells that express both T-cell receptors and NK-cell markers; they recognize lipid antigens presented by the CD1d molecule and produce large amounts of cytokines to modulate the immune response. This dual-cell approach aims to enhance anti-tumor activity and overcome immune evasion in patients with advanced or recurrent NSCLC.
- Other names
- NK and NKT cell immunotherapynatural killer + natural killer T cellnatural killer and natural killer T cell
02
Targets
NKG2D (Natural killer group 2 member D receptor)CD1D (Tumor-associated macrophage/myeloid-derived suppressor cell CD1d complex)
Beyond the preview
Go deeper on natural killer and natural killer T cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on natural killer and natural killer T cell therapy.